Active Substance: mycophenolate mofetil
Common Name: mycophenolate mofetil
ATC Code: L04AA06
Marketing Authorisation Holder: Roche Registration Ltd.
Active Substance: mycophenolate mofetil
Authorisation Date: 1996-02-14
Therapeutic Area: Graft Rejection
Pharmacotherapeutic Group: Immunosuppressants
CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
What is CellCept?
CellCept is a medicine containing the active substance mycophenolate mofetil. It is available as capsules (250 mg), tablets (500 mg), a powder to be made up into an oral suspension (1 g / 5 ml) and a powder to be made up into a solution for infusion (drip into a vein; 500 mg).
What is CellCept used for?
CellCept is used to prevent the body from rejecting a transplanted kidney, heart or liver. It is used with ciclosporin and corticosteroids (other medicines used to prevent organ rejection).
The medicine can only be obtained with a prescription.
How is CellCept used?
CellCept treatment should be initiated and maintained by a qualified transplant specialist.
The way that CellCept should be given and the dose depend on the type of organ transplant and the patient’s age and size.
For kidney transplants, the recommended dose in adults is 1.0 g twice a day by mouth (capsules, tablets or oral suspension) starting within 72 hours after the transplant. It can also be given as an infusion lasting two hours starting within 24 hours after the transplant, for up to 14 days. In children aged between two and 18 years, the dose of CellCept is calculated depending on height and weight and should be given by mouth.
For heart transplants, the recommended adult dose is 1.5 g twice a day by mouth, starting within five days following the transplant.
For liver transplants in adults, CellCept should be given as a 1-g infusion twice a day for the first four days after the transplant, before the patient is switched to 1.5 g twice a day by mouth as soon as it can be tolerated. CellCept is not recommended for use in children after heart or liver transplants because of a lack of information on its effects in this group.
The dose may need to be adjusted in patients with liver or kidney disease. For more information, see the summary of product characteristics (also part of the EPAR).
How does CellCept work?
The active substance in CellCept, mycophenolate mofetil, is an immunosuppressive medicine. In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase’. This enzyme is important for the formation of DNA in cells, particularly in the lymphocytes (a type of white blood cell which is involved in the rejection of organ transplants). By preventing the production of new DNA, CellCept reduces the rate at which the lymphocytes multiply. This makes them less effective at recognising and attacking the transplanted organ, lowering the risk of the organ being rejected.
How has CellCept been studied?
CellCept capsules and tablets have been studied in three studies involving a total of 1,493 adults following kidney transplant, in one study involving 650 adults following heart transplant and in one study involving 565 adults following liver transplant. CellCept was compared with azathioprine (another anti-rejection medicine) in all studies except for one of the kidney transplant studies, in which it was compared with placebo (a dummy treatment). A further study looked at the effect of CellCept oral suspension in 100 children following a kidney transplant. In all of the studies, all of the patients also received ciclosporin and corticosteroids, and the main measure of effectiveness was the proportion of patients whose new organ had been rejected after six months.
Further studies showed that the solution for infusion and the oral suspension produced similar levels of the active substance in the blood as the capsules.
What benefit has CellCept shown during the studies?
CellCept was as effective as azathioprine and more effective than placebo in preventing the rejection of transplanted kidneys after six months. In children undergoing kidney transplants, the rejection rates were similar to those seen in adults taking CellCept and lower than those seen in other studies of children who did not receive CellCept.
In the heart transplant study, around 38% of patients taking CellCept and those taking azathioprine experienced rejection after six months. Following liver transplant, 38% of the patients taking CellCept had rejected their new liver after six months, compared with 48% of those taking azathioprine, but the proportion of patients who had lost their new liver after a year was similar in the two groups, at around 4%.
What is the risk associated with CellCept?
The most serious risk associated with CellCept is the possible development of cancer, particularly lymphoma and skin cancer. The most common side effects with CellCept used in combination with ciclosporin and corticosteroids (seen in more than 1 patient in 10) are sepsis (blood infection), gastrointestinal candidiasis (a fungal infection of the stomach or gut), urinary-tract infection (infection of the structures that carry urine), herpes simplex (a viral infection that causes cold sores), herpes zoster (a viral infection that causes chickenpox and shingles), leucopenia (low white-blood-cell counts), thrombocytopenia (low blood platelet counts), anaemia (low red-blood-cell counts), vomiting, abdominal (tummy) pain, diarrhoea and nausea (feeling sick). For the full list of side effects reported with CellCept, see the package leaflet.
CellCept should not be used in people who may be hypersensitive (allergic) to mycophenolate mofetil or mycophenolic acid. It should not be used in women are breast-feeding. CellCept treatment is not recommended for use in pregnant women, and should only be started in women after a negative pregnancy test and if effective contraception is used before, during and for six weeks after CellCept treatment.
Why has CellCept been approved?
The Committee for Medicinal Products for Human Use (CHMP) decided that CellCept’s benefits are greater than its risks in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. The Committee recommended that CellCept be given marketing authorisation.
Other information about CellCept
The European Commission granted a marketing authorisation valid throughout the European Union for CellCept to Roche Registration Limited on 14 February 1996. The marketing authorisation was renewed on 14 February 2001 and on 14 February 2006.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.